International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 67

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 67

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 67

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

abexinostatum

abexinostat	3-[(dimethylamino)methyl]-*N*-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
abexinostat	3-[(diméthylamino)méthyl]-*N*-{2-[4-(hydroxycarbamoyl)phénoxy]éthyl}-1-benzofurane-2-carboxamide
abexinostat	3-[(dimetilamino)metil]-*N*-{2-[4-(hidroxicarbamoil)fenoxi]etil}-1-benzofuran-2-carboxamida

$C_{21}H_{23}N_3O_5$



amilomotidum #

amilomotide	virus like particle of bacteriophage Q-beta coat protein that is coupled to multiple copies of human beta-amyloid1-6 peptide fragment; reaction products of bacteriophage Q-beta coat protein with human beta-amyloid protein-(1-6)-peptidylglycylglycyl-L-cysteine and 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrole-1-yl)-*N*-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}propanamide
amilomotide	pseudo-particule virale de la capside du phage Q-bêta couplée à plusieurs copies du fragment 1-6 de la protéine bêta-amyloïde humaine; produit obtenu par réaction de la protéine de capside du phage Q-bêta avec la protéine bêta-amyloïde humaine-(1-6)peptidylglycylglycyl-L-cystéine et le 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrole-1-yl)-*N*-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}propanamide
amilomotida	pseudo-particula viral de cápsida del fago Q-beta acoplada a múltiples copias del fragmento 1-6 de la proteína beta-amiloide humana; producto obtenido por reacción de la proteína de cápsida del fago Q-beta con la proteína beta-amiloide humana-(1-6)peptidilglicilglicil-L-cisteína y el 3-(2,5-dioxo-2,5-dihidro-1*H*-pirrol-1-il)-*N*-{6-[(2,5-dioxopirrolidin-1-il)oxi]-6-oxohexil}propanamida

Heavy chain / Chaîne lourde / Cadena pesada

```
AKLETVTLGN IGKDGKQTLV LNPRGVNPTN GVASLSQAGA VPALEKRVTV 50
SVSQPSRNRK NYKVQVKIQN PTACTANGSC DPSVTRQAYA DVTFSFTQYS 100
TDEERAFVRT ELAALLASPL LIDAIDQLNP AY                    132
```

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
74-80

Modified residues / Résidus modifiés / Residuos modificados



anivamersenum

anivamersen

2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidine

anivamersen

2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidine

anivamersén

2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilctidina

$C_{157}H_{208}N_{56}O_{103}P_{14}$

(3'-5')-mC-mG-mC-mG-mG-mU-mA-mU-mA-mG-mU-mC-mC-mA-mC

asunaprevirum

asunaprevir

tert-butyl {(2*S*)-1-[(2*S*,4*R*)-4-({7-chloro-4-methoxyisoquinolin-1-yl}oxy)-2-({(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate

asunaprévir

(2*S*)-1-[(2*S*,4*R*)-4-({7-chloro-4-méthoxyisoquinolin-1-yl}oxy)-2-({(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-éthènylcyclopropyl}carbamoyl)pyrrolidin-1-yl]-3,3-diméthyl-1-oxobutan-2-yl}carbamate de *tert*-butyle

asunaprevir

{(2*S*)-1-[(2*S*,4*R*)-4-({7-cloro-4-metoxiisoquinolin-1-il}oxi)-2-({(1*R*,2*S*)-1-[(ciclopropanosulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]-3,3-dimetil-1-oxobutan-2-il}carbamato de *terc*-butilo

$C_{35}H_{46}ClN_5O_9S$



atecegatranum metoxilum

atecegatran metoxil

(2*S*)-1-{(2*R*)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl}-*N*-({4-[(*Z*)-*N*′-methoxycarbamimidoyl]phenyl}methyl)azetidine-2-carboxamide

atécégatran métoxil

(2*S*)-1-{(2*R*)-2-[3-chloro-5-(difluorométhoxy)phényl]-2-hydroxyacétyl}-*N*-({4-[(*Z*)-*N*′-méthoxycarbamimidoyl]phényl}méthyl)azétidine-2-carboxamide

atecegatrán metoxilo

(2*S*)-1-{(2*R*)-2-[3-cloro-5-(difluorometoxi)fenil]-2-hidroxiacetil}-*N*-({4-[(*Z*)-*N*′-metoxicarbamimidoil]fenil}metil)azetidina-2-carboxamida

$C_{22}H_{23}ClF_2N_4O_5$



avagacestatum

avagacestat — (2*R*)-2-(4-chloro-*N*-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}benzenesulfonamido)-5,5,5-trifluoropentanamide

avagacestat — (2*R*)-2-(4-chloro-*N*-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phényl]méthyl}benzenesulfonamido)-5,5,5-trifluoropentanamide

avagacestat — (2*R*)-2-(4-cloro-*N*-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)fenil]metil}bencenosulfonamido)-5,5,5-trifluoropentanamida

$C_{20}H_{17}ClF_4N_4O_4S$



besifovirum

besifovir — [({1-[(2-amino-9*H*-purin-9-yl)methyl]cyclopropyl}oxy)methyl]phosphonic acid

bésifovir — acide [({1-[(2-amino-9*H*-purin-9-yl)méthyl]cyclopropyl}oxy)méthyl]phosphonique

besifovir — ácido [({1-[(2-amino-9*H*-purin-9-il)metil]ciclopropil}oxi)metil]fosfónico

$C_{10}H_{14}N_5O_4P$



bitopertinum

bitopertin — {4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}[5-(methanesulfonyl)-2-{[(2*S*)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]methanone

bitopertine — {4-[3-fluoro-5-(trifluorométhyl)pyridin-2-yl]pipérazin-1-yl}[5-(méthanesulfonyl)-2-{[(2*S*)-1,1,1-trifluoropropan-2-yl]oxy}phényl]méthanone

bitopertina — {4-[3-fluoro-5-(trifluorometil)piridin-2-il]piperazin-1-il}[5-(metanosulfonil)-2-{[(2*S*)-1,1,1-trifluoropropan-2-il]oxy}fenil]metanona

$C_{21}H_{20}F_7N_3O_4S$



blosozumabum #

blosozumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* SOST (sclerostin)], humanized monoclonal antibody;
gamma4 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-24*01 (85.70%) -(IGHD)-IGHJ4*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 hinge S10>P (226), CH3 K120>del (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (84.00%) -IGKJ1*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (224-224":227-227")-bisdisulfide dimer

blosozumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* SOST (sclérostine)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-444) [VH humanisé (*Homo sapiens* IGHV1-24*01 (85.70%) -(IGHD)-IGHJ4*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 charnière S10>P (226), CH3 K120>del (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (84.00%) -IGKJ1*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (224-224":227-227")-bisdisulfure

blosozumab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* SOST (esclerostina)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-444) [VH humanizada (*Homo sapiens* IGHV1-24*01 (85.70%) -(IGHD)-IGHJ4*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 bisagra S10>P (226), CH3 K120>del (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-13*02 (84.00%) -IGKJ1*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (224-224":227-227")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKVSGFPIK DTFQHWVRQA PGKGLEWMGW  50
SDPEIGDTEY ASKFQGRVTM TEDTSTDTAY MELSSLRSED TAVYYCATGD 100
TTYKFDFWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLG       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVH TAVAWYQQKP GKAPKLLIYW  50
ASTRWTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSDYPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    145-201    259-319    365-423
         22"-96"  145"-201"  259"-319"  365"-423"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L 132-214' 132"-214'"
Inter-H-H 224-224" 227-227"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
295, 295"

brodalumabum #

brodalumab	immunoglobulin G2-kappa, anti-[*Homo sapiens* IL17RA (interleukin 17 receptor A, CD217)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-442) [*Homo sapiens* VH (IGHV1-18*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2*01 (117-442)], (130-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-15*01 (93.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (218-218":219-219":222-222":225-225")-tetrakisdisulfide dimer
brodalumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* IL17RA (récepteur A de l'interleukine 17, CD217)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-442) [*Homo sapiens* VH (IGHV1-18*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2*01 (117-442)], (130-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-15*01 (93.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfure
brodalumab	inmunoglobulina G2-kappa, anti-[IL17RA (receptor A de la interleukina 17 de *Homo sapiens*, CD217)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-442) [*Homo sapiens* VH (IGHV1-18*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2*01 (117-442)], (130-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-15*01 (93.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (218-218":219-219":222-222":225-225")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT RYGISWVRQA PGQGLEWMGW  50
ISTYSGNTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARRQ 100
LYFDYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200
VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV 300
LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWFQQKP GQAPRPLIYD  50
ASTRATGVPA RFSGSGSGTD FTLTISSLQS EDFAVYYCQQ YDNWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    143-199   256-316   362-420
         22"-96"  143"-199" 256"-316" 362"-420"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L 130-214' 130"-214'"
Inter-H-H 218-218" 219-219" 222-222" 225-225"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

292, 292"

cabozantinibum

cabozantinib	*N*-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
cabozantinib	*N*-{4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl}-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
cabozantinib	*N*-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

$C_{28}H_{24}FN_3O_5$



calaspargasum pegolum #

calaspargase pegol

pegylated *Escherichia coli* asparaginase;
[27-alanine,64-aspartic acid,252-threonine,263-asparagine]-L-asparaginase 2 (EC 3.5.1.1, L-asparagine amidohydrolase II) *Escherichia coli* (strain K12) tetramer α_4, carbamates with α-carboxy-ω-methoxypoly(oxyethylene)

calaspargase pégol

asparaginase d'*Escherichia coli* pégylée;
carbamates entre le tétramère α_4 de [27-alanine,64-acide aspartique,252-thréonine,263-asparagine]-L-asparaginase 2 (EC 3.5.1.1, L-asparagine amidohydrolase II) d'*Escherichia coli* (souche K12) et le α-carboxy-ω-méthoxypoly(oxyéthylène)

calaspargasa pegol

asparaginasa de *Escherichia coli* pegilada;
carbamatos entre el tetrámero α_4 de [27-alanina,64-ácido aspártico,252-treonina,263-asparagina]-L-asparaginasa 2 (EC 3.5.1.1, L-asparagina amidohidrolasa II) de *Escherichia coli* (cepa K12) y el α-carboxi-ω-metoxipoli(oxietileno)

$C_{1516}H_{2423}N_{415}O_{492}S_8$ (peptide monomer)

Monomer / Monomère / Monómero

```
LPNITILATG GTIAGGGDSA TKSNYTAGKV GVENLVNAVP QLKDIANVKG 50
EQVVNIGSQD MNDDVWLTLA KKINTDCDKT DGFVITHGTD TMEETAYFLD 100
LTVKCDKPVV MVGAMRPSTS MSADGPFNLY NAVVTAADKA SANRGVLVVM 150
NDTVLDGRDV TKTNTTDVAT FKSVNYGPLG YIHNGKIDYQ RTPARKHTSD 200
TPFDVSKLNE LPKVGIVYNY ANASDLPAKA LVDAGYDGIV SAGVGNGNLY 250
KTVFDTLATA AKNGTAVVRS SRVPTGATTQ DAEVDDAKYG FVASGTLNPQ 300
KARVLLQLAL TQTKDPQQIQ QIFNQY                           326
```

approximately 9 residues are pegylated out of 23 (1 L and 22 K)
environ 9 résidus sur 23 (1 L et 22 K) sont pegylés
aproximadamente están pegilados 9 restos de 23 (1L y 22K)



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
77-105 77'-105' 77'''-105''' 77''''-105''''

cantuzumabum ravtansinum #

cantuzumab ravtansine	immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242)], humanized monoclonal antibody conjugated to maytansinoid DM4; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer ; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [$N^{2'}$-deacetyl-$N^{2'}$-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate] For the *ravtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**
cantuzumab ravtansine	immunoglobuline G1-kappa, anti-[*Homo sapiens* glycane sialylé de MUC1, associé à des tumeurs (CA242, antigène du cancer 242)], anticorps monoclonal humanisé conjugué au maytansinoïde DM4; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [$N^{2'}$-déacétyl-$N^{2'}$-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle] Pour la partie *ravtansine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*
cantuzumab ravtansina	inmunoglobulina G1-kappa, anti-[*Homo sapiens* glicano sialilo de MUC1, asociado al tumor (CA242, antígeno del cancer 242)] anticuerpo monoclonal humanizado conjugado con el maitansinoide DM4; cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio, con el maitansinoide DM4 [$N^{2'}$-desacetil-$N^{2'}$-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el conector SPDB reducible [*N*-4-(2-piridilditio)butanoato de succinimidilo] Para la fracción *ravtansina*, se ruega referirse al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGETVKI SCKASDYTFT YYGMNWVKQA PGQGLKWMGW  50
IDTTTGEPTY AQKFQGRIAF SLETSASTAY LQIKSLKSED TATYFCARRG 100
PYNWYFDVWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS VPVTPGEPVS ISCRSSKSLL HSNGNTYLYW FLQRPGQSPQ  50
LLIYRMSNLV SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCLQHLEYP 100
FTFGPGTKLE LKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L 222-219' 222"-219'"
Inter-H-H 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

ceftolozanum

ceftolozane

(6*R*,7*R*)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1*H*-pyrazol-2-ium-2-yl)methyl]-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ceftolozane

(6*R*,7*R*)-3-[(5-amino-4-{[(2-aminoéthyl)carbamoyl]amino}-1-méthyl-1*H*-pyrazol-2-ium-2-yl)méthyl]-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acétamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

ceftolozano

(6*R*,7*R*)-3-[(5-amino-4-{[(2-aminoetil)carbamoil]amino}-1-metil-1*H*-pirazol-2-io-2-il)metil]-7-[(2*Z*)-2-(5-amino-1,2,4-tiadiazol-3-il)-2-{[(2-carboxipropan-2-il)oxo]imino}acetamido]-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxilato

$C_{23}H_{30}N_{12}O_8S_2$



cenderitidum

cenderitide

natriuretic peptide receptor type B (NPR-B) agonist;
human C-type natriuretic peptide-(32-53)-peptide (CNP-22) fusion protein with eastern green mamba (*Dendroaspis angusticeps*) natriuretic peptide-(24-38)-peptide

cendéritide

agoniste du récepteur du peptide natriurétique de type B;
peptide natriurétique de type-C humain-(32-53)-peptide (CNP-22) protéine de fusion avec le peptide natriurétique de *Dendroaspis angusticeps* (mamba vert)-(24-38)-peptide

cenderitida

agonista del receptor del péptido natriurético de tipo B;
péptido natriurético de tipo-C humano-(32-53)-péptido (CNP-22) proteína de fusión con el péptido natriurético de *Dendroaspis angusticeps* (mamba vert)-(24-38)-péptido

$C_{158}H_{263}N_{49}O_{50}S_3$

```
GLSKGCFGLK  LDRIGSMSGL  GCPSLRDPRP  NAPSTSA 37
```

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
6-22

cepeginterferonum alfa-2b #
cepeginterferon alfa-2b

pegylated human interferon alpha-2b;
$N^{2.1}$-{4-[ω-methoxypoly(oxyethylene)]butyl}-human interferon alpha-2b

cépeginterféron alfa-2b

interféron alpha-2b humain pégylé;
$N^{2.1}$-{4-[ω-méthoxypoly(oxyéthylène)]butyl}-interféron alpha-2b humain

cepeginterferón alfa-2b

interferón alfa-2b humano pegilado;
$N^{2.1}$-{4-[ω-metoxipoli(oxietileno)]butil}-interferón alfa-2b humano

$C_{865}H_{1359}N_{229}O_{256}S_9\ [C_2H_4O]_n$

```
CDLPQTHSLG SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA 50
ETIPVLHEMI QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI 100
QGVGVTETPL MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS 150
FSLSTNLQES LRSKE                                      165
```

Disulfide bridges location / Positions des ponts disulfure / Posiciones de los puentes disulfuro
1-98 29-138

Modified residue / Résidu modifié / Residuo modificado



conberceptum #
conbercept

fusion protein for immune applications (FPIA) comprising *Homo sapiens* FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR1, vascular permeability factor receptor, tyrosine-protein kinase FRT) fragment, fused with *Homo sapiens* KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, protein-tyrosine kinase receptor FLK1, CD309) fragment, fused with *Homo sapiens* immunoglobulin G1 Fc fragment;
FLT1, 132-232 precursor fragment (1-101) -KDR, 227-421 precursor fragment (102-296) -glycyl-prolyl-glycyl (297-299) -gamma1 chain H-CH2-CH3 fragment (300-526) [*Homo sapiens* IGHG1*03 hinge 6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)]; (305-305':308-308')-bisdisulfide dimer

conbercept

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* FLT1 (tyrosine kinase 1 apparentée au fms, récepteur 1 du facteur de croissance de l'endothélium vasculaire, VEGFR1, récepteur du facteur de perméabilité vasculaire, tyrosine-protéine kinase FRT), fusionné à un fragment *d'Homo sapiens* KDR (récepteur à domaine kinase, récepteur 2 du facteur de croissance de l'endothélium vasculaire, VEGFR2, récepteur tyrosine-protéine kinase FLK1, CD309), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1;
FLT1, fragment 132-232 du précurseur (1-101) -KDR, fragment 227-421 du précurseur (102-296) - glycyl-prolyl-glycyl (297-299) - fragment H-CH2-CH3 de la chaîne gamma1 (300-526) [*Homo sapiens* IGHG1*03 charnière 6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)]; dimère (305-305':308-308')-bisdisulfure

conbercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de FLT1 de *Homo sapiens* (tirosina kinasa 1 relacionada con fms, receptor 1 del factor de crecimiento del endotelio vascular, VEGFR1, receptor del factor de permeabilidad vascular, tirosina-protein kinasa FRT), fusionada a un fragmento *de* KDR de *Homo sapiens* (receptor con dominio kinasa, receptor 2 del factor de crecimiento del endotelio vascular, VEGFR2, receptor tirosina-protein kinasa FLK1, CD309), fusionado al fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*;
FLT1, fragmento 132-232 de precursor (1-101) -KDR, fragmento 227-421 del precursor (102-296) - glicil-prolil-glicil (297-299) - fragmento H-CH2-CH3 de la cadena gamma1 (300-526) [*Homo sapiens* IGHG1*03 bisagra 6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)]; dímero (305-305':308-308')-bisdisulfuro

Fused chain / chaine fusionnée / cadena fusionada

```
GRPFVEMYSE IPEIIHMTEG RELVIPCRVT SPNITVTLKK FPLDTLIPDG  50
KRIIWDSRKG FIISNATYKE IGLLTCEATV NGHLYKTNYL THRQTNTIID 100
VVLSPSHGIE LSVGEKLVLN CTARTELNVG IDFNWEYPSS KHQHKKLVNR 150
DLKTQSGSEM KKFLSTLTID GVTRSDQGLY TCAASSGLMT KKNSTFVRVH 200
EKPFVAFGSG MESLVEATVG ERVRIPAKYL GYPPPEIKWY KNGIPLESNH 250
TIKAGHVLTI MEVSERDTGN YTVILTNPIS KEKQSHVVSL VVYVPPGPGD 300
KTHTCPLCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP 350
EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC 400
KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG 450
FYPSDIAVEW ESNGQPENNY KATPPVLDSD GSFFLYSKLT VDKSRWQQGN 500
VFSCSVMHEA LHNHYTQKSL SLSPGK                           526
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain	27-76	121-182	340-400	446-504
	27'-76'	121'-182'	340'-400'	446'-504'
Inter-chains	305-305'	308-308'		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
376, 376'

crenezumabum #

crenezumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* amyloid beta (Abeta) peptides Aβ42 and Aβ40)], humanized monoclonal antibody; gamma4 heavy chain (1-438) [humanized VH (*Homo sapiens* IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5] (1-112) -*Homo sapiens* IGHG4*01 hinge S10>P (220) (113-438)], (126-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (218-218":221-221")-bisdisulfide dimer

crénezumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* peptides *bêta-amyloïdes* (*Abêta)* Aβ42 et Aβ40)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-438) [VH humanisé (*Homo sapiens* IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5] (1-112) -*Homo sapiens* IGHG4*01 charnière S10>P (220) (113-438)], (126-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (218-218":221-221")-bisdisulfure

crenezumab

inmunoglobulina G4-kappa, anti-[péptidos *beta-amiloides* (*Abeta)* Aβ42 y Aβ40 de *Homo sapiens*)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-438) [VH humanizada (*Homo sapiens* IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5] (1-112) -*Homo sapiens* IGHG4*01 bisagra S10>P (220) (113-438)], (126-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (218-218":221-221")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMSWVRQA PGKGLELVAS  50
INSNGGSTYY PDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCASGD 100
YWGQGTTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK 200
PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK DTLMISRTPE 250
VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV 300
LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM 350
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS 400
RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLG              438
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS LPVTPGEPAS ISCRSSQSLV YSNGDTYLHW YLQKPGQSPQ  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96     139-195     253-313     359-417
          22"-96"   139"-195"   253"-313"   359"-417"
Intra-L   23'-93'     139'-199'
          23'"-93'"   139'"-199'"
Inter-H-L 126-219'    126"-219'"
Inter-H-H 218-218"    221-221"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
289, 289"

crenolanibum

crenolanib

1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1*H*-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine

crénolanib

1-(2-{5-[(3-méthyloxétan-3-yl)méthoxy]-1*H*-benzimidazol-1-yl}quinoléin-8-yl)pipéridin-4-amine

crenolanib

1-(2-{5-[(3-metiloxetan-3-il)metoxi]-1*H*-benzoimidazol-1-il}quinolin-8-il)piperidin-4-amina

$C_{26}H_{29}N_5O_2$



dabrafenibum

dabrafenib — *N*-{3-[5-(2-aminopyrimidin-4-yl)-2-*tert*-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide

dabrafénib — *N*-{3-[5-(2-aminopyrimidin-4-yl)-2-*tert*-butyl-1,3-thiazol-4-yl]-2-fluorophényl}-2,6-difluorobenzènesulfonamide

dabrafenib — *N*-{3-[5-(2-aminopirimidin-4-il)-2-*terc*-butil-1,3-tiazol-4-il]-2-fluorofenil}-2,6-difluorobencenosulfonamido

$C_{23}H_{20}F_3N_5O_2S_2$



daclatasvirum

daclatasvir — dimethyl *N*,*N*′-([1,1'-biphenyl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(1*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate

daclatasvir — *N*,*N*′-([1,1'-biphényl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(1*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

daclatasvir — *N*,*N*′-([1,1'-bifenil]-4,4'-diilbis{1*H*-imidazol-5,2-diil-[(2*S*)-pirrolidina-2,1-diil][(1*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

$C_{40}H_{50}N_8O_6$



dalanterceptum #

dalantercept

fusion protein for immune applications (FPIA) comprising *Homo sapiens* ACVRL1 (activin A receptor type II-like 1, activin receptor-like kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, transforming growth factor-beta superfamily receptor type I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2) fragment, fused with *Homo sapiens* immunoglobulin G1 Fc fragment; ACVR2L1, 22-120 precursor fragment (1-99) -threonyl-triglycyl (100-103) -gamma1 chain H-CH2-CH3 fragment (104-328) [*Homo sapiens* IGHG1*03 hinge 8-15 (104-111), CH2 L1.3>A (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)]; (107-107':110-110')-bisdisulfide dimer

dalantercept

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* ACVRL1 (récepteur 1 de type II-like de l'activine A, kinase 1 apparentée au récepteur de l'activine, ALK1, ALK-1, récepteur R3 de type sérine/thréonine-protéine kinase, SKR3, récepteur de type I de la superfamille du facteur de croissance transformant bêta, récepteur de type I de la superfamille du TGF-B, TSR-I, HHT2, ORW2), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1;
ACVR2L1, fragment 22-120 du précurseur (1-99) -thréonyl-triglycyl (100-103) -fragment H-CH2-CH3 de la chaîne gamma1 (104-328) [*Homo sapiens* IGHG1*03 charnière 8-15 (104-111), CH2 L1.3>A (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)]; dimère (107-107':110-110')-bisdisulfure

dalantercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVRL1 de *Homo sapiens* (receptor 1 de tipo II-like de la activina A, kinasa 1 relacionada con el receptor de la activina, ALK1, ALK-1, receptor R3 de tipo serina/treonina-proteinkinasa, SKR3, receptor de tipo I de la superfamilia del factor de crecimiento transformador beta, receptor de tipo I de la superfamilia del TGF-B, TSR-I, HHT2, ORW2), fusionada con el fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*;
ACVR2L1, fragmento 22-120 del precursor (1-99) -treonil-triglicil (100-103) -fragmento H-CH2-CH3 de la cadena gamma1 (104-328) [*Homo sapiens* IGHG1*03 bisagra 8-15 (104-111), CH2 L1.3>A (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)]; dímero (107-107':110-110')-bisdisulfuro

Fused chain / chaine fusionnée / cadena fusionada

```
DPVKPSRGPL VTCTCESPHC KGPTCRGAWC TVVLVREEGR HPQEHRGCGN  50
LHRELCRGRP TEFVNHYCCD SHLCNHNVSL VLEATQPPSE QPGTDGQLAT 100
GGGTHTCPPC PAPEALGAPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE 150
DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY 200
KCKVSNKALP VPIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV 250
KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGPFFLYSK LTVDKSRWQQ 300
GNVFSCSVMH EALHNHYTQK SLSLSPGK                         328
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain 13-30 15-20 25-48 56-68 69-74 142-202 248-306
13'-30' 15'-20' 25'-48' 56'-68' 69'-74' 142'-202' 248'-306'
Inter-chains 107-107' 110-110'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
77, 178, 77', 178'

dasolampanelum

dasolampanel	(3*S*,4a*S*,6*S*,8a*R*)-6-[3-chloro-2-(1*H*-tetrazol-5-yl)phenoxy]-decahydroisoquinoline-3-carboxylic acid
dasolampanel	acide (3*S*,4a*S*,6*S*,8a*R*)-6-[3-chloro-2-(1*H*-tétrazol-5-yl)phénoxy]décahydroisoquinoléine-3-carboxylique
dasolampanel	ácido (3*S*,4a*S*,6*S*,8a*R*)-6-[3-cloro-2-(1*H*-tetrazol-5-il)fenoxi]-decahidroisoquinolina-3-carboxilico

$C_{17}H_{20}ClN_5O_3$



delanzomibum

delanzomib	{(1*R*)-1-[(2*S*,3*R*)-3-hydroxy-2-(6-phenylpyridine-2-carboxamido)butanamido]-3-methylbutyl}boronic acid
délanzomib	acide {(1*R*)-1-[(2*S*,3*R*)-3-hydroxy-2-(6-phénylpyridine-2-carboxamido)butanamido]-3-méthylbutyl}boronique
delanzomib	ácido {(1*R*)-1-[(2*S*,3*R*)-3-hidroxi-2-(6-fenilpiridina-2-carboxamido)butanamido]-3-metilbutil}borónico

$C_{21}H_{28}BN_3O_5$



delcasertibum

delcasertib	human immunodeficiency virus 1 protein Tat-(46-57)-peptide (1→1')-disulfide with L-cysteinyl-[mouse protein kinase C delta type-(8-17)-peptide]
delcasertib	protéine Tat du virus 1 de l'immunodéficience humaine-(46-57)-peptide (1→1')-disulfure avec le L-cystéinyl-(protéine kinase C type delta de souris-(8-17)-peptide
delcasertib	proteína Tat del virus 1 de la inmunodeficiencia humana-(46-57)-péptido (1→1')-disulfuro con la L-cisteinil-[proteína kinasa C tipo delta de ratón-(8-17)-péptido]

$C_{120}H_{199}N_{45}O_{34}S_2$

A chain / Chaîne A / Cadena A
CYGRKKRRQR RR 12

Light chain / Chaîne légère / Cadena ligera
CSFNSYELGS L 11'

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
1-1'

dolutegravirum

dolutegravir — (4*R*,12a*S*)-*N*-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2*H*-pyrido[1',2':4,5]pyrazino[2,1-*b*][1,3]oxazine-9-carboxamide

dolutégravir — (4*R*,12a*S*)-*N*-[(2,4-difluorophényl)méthyl]-7-hydroxy-4-méthyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2*H*-pyrido[1',2':4,5]pyrazino[2,1-*b*][1,3]oxazine-9-carboxamide

dolutegravir — (4*R*,12a*S*)-*N*-[(2,4-difluorofenil)metil]-7-hidroxi-4-metil-6,8-dioxo-3,4,6,8,12,12a-hexahidro-2*H*-pirido[1',2':4,5]pirazino[2,1-*b*][1,3]oxazina-9-carboxamida

$C_{20}H_{19}F_2N_3O_5$



encaleretum

encaleret — 2′-{(1*R*)-1-[(2*R*)-3-{[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino}-2-hydroxypropoxy]ethyl}-3-methyl[1,1′-biphenyl]-4-carboxylic acid

encaléret — acide 2′-{(1*R*)-1-[(2*R*)-3-{[1-(4-chloro-3-fluorophényl)-2-méthylpropan-2-yl]amino}-2-hydroxypropoxy]éthyl}-3-méthyl[1,1′-biphényl]-4-carboxylique

encaleret — ácido 2′-{(1*R*)-1-[(2*R*)-3-{[1-(4-cloro-3-fluorofenil)-2-metilpropan-2-yl]amino}-2-hidroxipropoxi]etil}-3-metil[1,1′-bifenil]-4-carboxílico

$C_{29}H_{33}ClFNO_4$



epelsibanum

epelsiban — (3*R*,6*R*)-3-(2,3-dihydro-1*H*-inden-2-yl)-1-[(1*R*)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoethyl]-6-[(2*S*)-butan-2-yl]piperazine-2,5-dione

épelsiban — (3*R*,6*R*)-3-(2,3-dihydro-1*H*-indén-2-yl)-1-[(1*R*)-1-(2,6-diméthylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(2*S*)-butan-2-yl]pipérazine-2,5-dione

epelsibán — (3*R*,6*R*)-3-(2,3-dihidro-1*H*-inden-2-il)-1-[(1*R*)-1-(2,6-dimetilpiridin-3-il)-2-(morfolin-4-il)-2-oxoetil]-6-[(2*S*)-butan-2-il]piperazina-2,5-diona

$C_{30}H_{38}N_4O_4$



etoxybamidum

etoxybamide — 4-hydroxy-*N*-(2-hydroxyethyl)butanamide

étoxybamide — 4-hydroxy-*N*-(2-hydroxyéthyl)butanamide

etoxibamida — 4-hidroxi-*N*-(2-hidroxietil)butanamida

$C_6H_{13}NO_3$



evacetrapibum

evacetrapib — (1*r*,4*r*)-4-({(5*S*)-5-[{[3,5-bis(trifluoromethyl)phenyl]methyl}(2-methyl-2*H*-tetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl}methyl)cyclohexane-1-carboxylic acid

évacétrapib — acide (1*r*,4*r*)-4-({(5*S*)-5-[{[3,5-bis(trifluorométhyl)phényl]méthyl}(2-méthyl-2*H*-tétrazol-5-yl)amino]-7,9-diméthyl-2,3,4,5-tétrahydro-1*H*-benzazépin-1-yl}méthyl)cyclohexane-1-carboxylique

evacetrapib — ácido (1*r*,4*r*)-4-({(5*S*)-5-[{[3,5-bis(trifluorometil)fenil]metil}(2-metil-2*H*-tetrazol-5-il)amino]-7,9-dimetil-2,3,4,5-tetrahidro-1*H*-1-benzazepin-1-il}metil)ciclohexano-1-carboxílico

$C_{31}H_{36}F_6N_6O_2$



exeporfinii chloridum

exeporfinium chloride — 3,3'-(21*H*,23*H*-porphyrin-5,15-diylbis{[(4,1-phenylene)oxy]-*N,N,N*-trimethylpropan-1-aminium}) dichloride

chlorure d'exéporfinium — dichlorure de 3,3'-[21*H*,23*H*-porphyrin-5,15-diylbis(4,1-phénylèneoxy)]bis[*N,N,N*-triméthylpropan-1-aminium]

cloruro de exeporfinio — dicloruro de 3,3'-(21*H*,23*H*-porfirin-5,15-diilbis{[(4,1-fenileno)oxi]-*N,N,N*-trimetilpropan-1-aminium})

$C_{44}H_{50}Cl_2N_6O_2$



fabomotizolum

fabomotizole — 5-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1*H*-benzimidazole

fabomotizole — 5-éthoxy-2-{[2-(morpholin-4-yl)éthyl]sulfanyl}-1*H*-benzimidazole

fabomotizol — 5-etoxi-2-{[2-(morfolin-4-il)etil]sulfanil}-1*H*-benzoimidazol

$C_{15}H_{21}N_3O_2S$



faciniclinum

facinicline — *N*-[(3*S*)-1-azabicyclo[2.2.2]octan-3-yl]-1*H*-indazole-3-carboxamide

facinicline — *N*-[(3*S*)-1-azabicyclo[2.2.2]octan-3-yl]-1*H*-indazole-3-carboxamide

faciniclina — *N*-[(3*S*)-1-azabiciclo[2.2.2]octan-3-il]-1*H*-indazol-3-carboxamida

$C_{15}H_{18}N_4O$



fiboflaponum

fiboflapon	3-{3-(*tert*-butylsulfanyl)-1-{[4-(6-ethoxypyridin-3-yl)phenyl]methyl}-5-[(5-methylpyridin-2-yl)methoxy]-1*H*-indol-2-yl}-2,2-dimethylpropanoic acid
fiboflapon	acide 3-{3-(*tert*-butylsulfanyl)-1-{[4-(6-éthoxypyridin-3-yl)phényl]méthyl}-5-[(5-méthylpyridin-2-yl)méthoxy]-1*H*-indol-2-yl}-2,2-diméthylpropanoïque
fiboflapón	ácido 3-{3-(*terc*-butilsulfanil)-1-{[4-(6-etoxipiridin-3-il)fenil]metil}-5-[(5-metilpiridin-2-il)metoxi]-1*H*-indol-2-yl}-2,2-dimetilpropanoico

$C_{38}H_{43}N_3O_4S$



ficlatuzumabum #

ficlatuzumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* HGF (hepatocyte growth factor, scatter factor, SF, hepatopoeitin A)], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03 (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (227-227":230-230")-bisdisulfide dimer
ficlatuzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* HGF (facteur de croissance de l'hépatocyte, facteur dispersant, SF, hépatopoïétine A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03 (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

ficlatuzumab

inmunoglobulina G1-kappa, anti-[HGF de *Homo sapiens* (factor de crecimiento del hepatocito, factor dispersante, SF, hepatopoyetina A)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03 (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQPGAE VKKPGTSVKL SCKASGYTFT TYWMHWVRQA PGQGLEWIGE  50
INPTNGHTNY NQKFQGRATL TVDKSTSTAY MELSSLRSED TAVYYCARNY 100
VGSIFDYWGQ GTLLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAMSLGERVT LNCKASENVV SYVSWYQQKP GQSPKLLIYG  50
ASNRESGVPD RFSGSGSATD FTLTISSVQA EDVADYHCGQ SYNYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    145-201    262-322    368-426
         22"-96"  145"-201"  262"-322"  368"-426"
Intra-L  23'-88'    134'-194'
         23'"-88'"  134'"-194'"
Inter-H-L  221-214'  221"-214'"
Inter-H-H  227-227"  230-230"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"

galeteronum

galeterone

17-(1*H*-benzimidazol-1-yl)androsta-5,16-dien-3β-ol

galétérone

17-(1*H*-benzimidazol-1-yl)androsta-5,16-dién-3β-ol

galeterona

17-(1*H*-benzoimidazol-1-il)androsta-5,16-dien-3β-ol

$C_{26}H_{32}N_2O$



ganetespibum

ganetespib

5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1*H*-indol-5-yl)-2,4-dihydro-3*H*-1,2,4-triazol-3-one

ganétespib

5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-4-(1-méthyl-1*H*-indol-5-yl)-2,4-dihydro-3*H*-1,2,4-triazol-3-one

ganetespib

5-[2,4-dihidroxi-5-(propan-2-il)fenil]-4-(1-metil-1*H*-indol-5-il)-2,4-dihidro-3*H*-1,2,4-triazol-3-ona

$C_{20}H_{20}N_4O_3$



indatuximabum ravtansinum #

indatuximab ravtansine — immunoglobulin G4-kappa, anti-[*Homo sapiens* SDC1 (syndecan-1, CD138)], chimeric monoclonal antibody conjugated to maytansinoid DM4;
gamma4 heavy chain (1-449) [*Mus musculus* VH (IGHV1-9*01 -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01 (123-449)], (136-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [$N^{2'}$-deacetyl-$N^{2'}$-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate]
For the *ravtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**

indatuximab ravtansine — immunoglobuline G4-kappa, anti-[*Homo sapiens* SDC1 (syndecan-1, CD138)], anticorps monoclonal chimérique conjugué au maytansinoïde DM4;
chaîne lourde gamma4 (1-449) [*Mus musculus* VH (IGHV1-9*01 -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01 (123-449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [$N^{2'}$-déacétyl-$N^{2'}$-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle]
Pour la partie *ravtansine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

indatuximab ravtansina — inmunoglobulina G4-kappa, anti-[SDC1 de *Homo sapiens* (sindecán-1, CD138)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM4;
cadena pesada gamma4 (1-449) [*Mus musculus* VH (IGHV1-9*01 -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01 (123-449)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio con el maitansinoide DM4 [$N^{2'}$-desacetil-$N^{2'}$-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el espaciador SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo]
Para la fracción *ravtansina*, se ruega referirse al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"**

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGSE LMMPGASVKI SCKATGYTFS NYWIEWVKQR PGHGLEWIGE  50
ILPGTGRTIY NEKFKGKATF TADISSNTVQ MQLSSLTSED SAVYYCARRD 100
YYGNFYYAMD YWGQGTSVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSTSS LSASLGDRVT ISCSASQGIN NYLNWYQQKP DGTVELLIYY  50
TSTLQSGVPS RFSGSGSGTD YSLTISNLEP EDIGTYYCQQ YSKLPRTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-205 263-323 369-437
22''-96'' 149''-205'' 263''-323'' 369''-437''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 136-214' 136''-214'''
Inter-H-H 228-228'' 231-231''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299''

iofolastatum (^{123}I)

iofolastat (^{123}I) — *N*-{[(1*S*)-1-carboxy-5-{[(4-(^{123}I)iodophenyl)methyl]amino}pentyl]carbamoyl}-L-glutamic acid

iofolastat (^{123}I) — acide *N*-{[(1*S*)-1-carboxy-5-{[(4-(^{123}I)iodophényl)méthyl]amino}pentyl]carbamoyl}-L-glutamique

iofolastat (^{123}I) — ácido *N*-{[(1*S*)-1-carboxi-5-{[(4-(^{123}I)iodofenil)metil]amino}pentil]carbamoil}-L-glutámico

$C_{19}H_{26}{}^{123}IN_3O_7$



irdabisantum

irdabisant — 6-(4-{3-[(2*R*)-2-methylpyrrolidin-1-yl]propoxy}phenyl)pyridazin-3(2*H*)-one

irdabisant — 6-(4-{3-[(2*R*)-2-méthylpyrrolidin-1-yl]propoxy}phényl)pyridazin-3(2*H*)-one

irdabisant — 6-(4-{3-[(2*R*)-2-metilpirrolidin-1-il]propoxi}fenil)piridazin-3(2*H*)-ona

$C_{18}H_{23}N_3O_2$



ixekizumabum #

ixekizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody;
gamma4 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 hinge S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (225-225":228-228")-bisdisulfide dimer

ixékizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-445) [VH humanisé (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 charnière S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (225-225":228-228")-bisdisulfure

ixekizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-445) [VH humanizada (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 bisagra S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYSFT DYHIHWVRQA PGQGLEWMGV  50
INPMYGTTDY NQRFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD 100
YFTGTGVYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSRSLV HSRGNTYLHW YLQKPGQSPQ  50
LLIYKVSNRF IGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHLP 100
FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	260-320	366-424
	22"-96"	146"-202"	260"-320"	366"-424"
Intra-L	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L	133-219'	133"-219'"		
Inter-H-H	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
296, 296"

ladarixinum

ladarixin

4-[(2*R*)-1-oxo-1-(methanesulfonamido)propan-2-yl]phenyl trifluoromethanesulfonate

ladarixine

trifluorométhanesulfonate de 4-[(2*R*)-1-oxo-1-(méthanesulfonamido)propan-2-yl]phényle

ladarixina

trifluoromethanesulfonato de 4-[(2*R*)-1-oxo-1-(metanosulfonamido)propan-2-il]fenil

$C_{11}H_{12}F_3NO_6S_2$



lenomorelinum

lenomorelin

$O^{3.26}$-octanoylhuman appetite-regulating hormone (growth hormone-releasing peptide) precursor (protein M46)-(24-51)-peptide (ghrelin-28-C8)

lénomoréline

$O^{3.26}$-octanoylprécurseur de l'hormone humaine de régulation de l'appétit (précurseur du peptide de libération d'hormone de croissance, protéine M46)-(24-51)-peptide (ghréline-28-C8)

lenomorelina

$O^{3.26}$-octanoilprecursor de la hormona humana de regulación del apetito (precursor del péptido de liberación de hormona del crecimiento, proteína M46)-(24-51)-péptido (ghrelina-28-C8)

$C_{149}H_{249}N_{47}O_{42}$

GSSFLSPEHQ RVQQRKESKK PPAKLQPR 28

Modified residue / Résidu modifié / Residuo modificado

S
3
O-octanoyl-L-seryl
O-octanoyl-L-séryl
O-octanoil-L-serilo



lesinuradum

lesinurad

2-{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-yl]sulfanyl}acetic acid

lésinurad

acide 2-{[5-bromo-4-(4-cyclopropylnaphtalén-1-yl)-4*H*-1,2,4-triazol-3-yl]sulfanyl}acétique

lesinurad

ácido 2-{[5-bromo-4-(4-ciclopropilnaftalen-1-il)-4*H*-1,2,4-triazol-3-il]sulfanil}acético

$C_{17}H_{14}BrN_3O_2S$



lexibulinum

lexibulin

1-ethyl-3-[2-methoxy-4-(5-methyl-4-{[(1*S*)-1-(pyridin-3-yl)butyl]amino}pyrimidin-2-yl)phenyl]urea

lexibuline

1-éthyl-3-[2-méthoxy-4-(5-méthyl-4-{[(1*S*)-1-(pyridin-3-yl)butyl]amino}pyrimidin-2-yl)phényl]urée

lexibulina

1-etil-3-[2-metoxi-4-(5-metil-4-{[(1*S*)-1-(piridin-3-il)butil]amino}pirimidin-2-il)fenil]urea

$C_{24}H_{30}N_6O_2$



lipegfilgrastimum #

lipegfilgrastim

pegylated granulocyte colony stimulating factor; $O^{3.133}$-[N^5-(*N*-{[ω-methoxypoly(oxyethylene)]carbonyl}glycyl)-α-neuraminyl-(2→6)-α-D-galactopyranosyl]-L-methionyl-des-1-L-alanine-des-37-L-valine-des-38-L-serine-des-39-L-glutamic acid-human granulocyte colony-stimulating factor (G-CSF, pluripoietin)

lipegfilgrastim

facteur de stimulation de colonie de granulocytes humain pégylé; $O^{3.133}$-[N^5-(*N*-{[ω-méthoxypoly(oxyéthylène)]carbonyl}glycyl)-α-neuraminyl-(2→6)-α-D-galactopyranosyl]-L-méthionyl-dès-1-L-alanine-dès-37-L-valine-des-38-L-sérine-dès-39-L-acide glutamique-facteur de stimulation de colonie de granulocytes humain (G-CSF, pluripoïétine)

lipegfilgrastim

factor de estimulación de colonias de granulocitos humano pegilado; $O^{3.133}$-[N^5-(*N*-{[ω-metoxipoli(oxietileno)]carbonil}glicil)-α-neuraminil-(2→6)-α-D-galactopiranosil]-L-metionil-des-1-L-alanina-des-37-L-valina-des-38-L-serine-des-39-L-ácido glutámico-factor de estimulación de colonias de granulocitos humanos (G-CSF, pluripoyetina)

$C_{864}H_{1369}N_{225}O_{258}S_9$ $[C_2H_4O]_n$

```
                                                        M 0
TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
VLVASHLQSF LEVSYRVLRH LAQP                              174
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
36-42 64-74

Modified residue / Résidu modifié / Residuo modificado



loredіplonum

loredіplon — *N*-{2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-*a*]pyrimidin-7-yl]phenyl}-*N*-methylacetamide

lorédіplon — *N*-{2-fluoro-5-[3-(thiophéne-2-carbonyl)pryrazolo[1,5-*a*]pyrimidin-7-yl]phényl}-*N*-méthylacétamide

lorediplón — *N*-{2-fluoro-5-[3-(tiofeno-2-carbonil)pirazolo[1,5-*a*]pirimidin-7-il]fenil}-*N*-metilacetamida

$C_{20}H_{15}FN_4O_2S$



lumacaftorum

lumacaftor — 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido]-3-methylpyridin-2-yl}benzoic acid

lumacaftor — acide 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido]-3-methylpyridin-2-yl}benzoïque

lumacaftor — ácido 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-il)ciclopropano-1-carboxamido]-3-metilpiridin-2-il}benzoico

$C_{24}H_{18}F_2N_2O_5$



lurbinectedinum

lurbinectedin — (1'*R*,6*R*,6a*R*,7*R*,13*S*,14*S*,16*R*)-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-19-oxo-2',3',4',6,7,9',12,13,14,16-decahydro-6a*H*-spiro[7,13-azano-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-pyrido[3,4-b]indol]-5-yl acetate

lurbinectédine — acétate de (1'*R*,6*R*,6a*R*,7*R*,13*S*,14*S*,16*R*)-8,14-dihydroxy-6',9-diméthoxy-4,10,23-triméthyl-19-oxo-2',3',4',6,7,9',12,13,14,16-décahydro-6a*H*-spiro[7,13-azano-6,16-(épithiopropanooxyméthano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-pyrido[3,4-b]indol]-5-yl

lurbinectedina — acetato de (1'*R*,6*R*,6a*R*,7*R*,13*S*,14*S*,16*R*)-8,14-dihidroxi-6',9-dimetoxi-4,10,23-trimetil-19-oxo-2',3',4',6,7,9',12,13,14,16-decahidro-16*H*-spiro[7,13-azano-6,16-(epitiopropanooximetano)[1,3]dioxolo[7,8]isoquinolino[3,2-*b*][3]benzazocina-20,1'-pirido[3,4-*b*]indol]-5-ilo

$C_{41}H_{44}N_4O_{10}S$



melphalanum flufenamidum

melphalan flufenamide	ethyl (2*S*)-2-[(2*S*)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanamido]-3-(4-fluorophenyl)propanoate
melphalan flufénamide	(2*S*)-2-[(2*S*)-2-amino-3-{4-[bis(2-chloroéthyl)amino]phényl}propanamido]-3-(4-fluorophényl)propanoate d'éthyle
melfalán flufenamida	(2*S*)-2-[(2*S*)-2-amino-3-{4-[bis(2-cloroetil)amino]fenil}propanamido]-3-(4-fluorofenil)propanoato de etilo

$C_{24}H_{30}Cl_2FN_3O_3$



mericitabinum

mericitabine	(2'*R*)-2'-deoxy-2'-fluoro-2'-methyl-2',3'-bis-*O*-(2-methylpropanoyl)cytidine
méricitabine	3',5'-bis(2-méthylpropanoate) de (2'*R*)-2'-déoxy-2'-fluoro-2'-méthylcytidine
mericitabina	(2'*R*)-2'-desoxi-2'-fluoro-2'-metil-2',3'-bis-*O*-(2-metilpropanoil)citidina

$C_{18}H_{26}FN_3O_6$



milciclibum

milciclib	*N*,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide
milciclib	*N*,1,4,4-tétraméthyl-8-{[4-(4-méthylpipérazin-1-yl)phényl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide
milciclib	*N*,1,4,4-tetrametil-8-{[4-(4-metilpiperazin-1-il)fenil]amino}-4,5-dihidro-1*H*-pirazolo[4,3-*h*]quinazolina-3-carboxamida

$C_{25}H_{32}N_8O$



naldemedinum

naldemedine	17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-*N*-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide
naldémédine	17-(cyclopropylméthyl)-6,7-didéhydro-4,5α-époxy-3,6,14-trihydroxy-*N*-[2-(3-phényl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide
naldemedina	17-(ciclopropilmetil)-6,7-didehidro-4,5α-epoxi-3,6,14-trihidroxi-*N*-[2-(3-fenil-1,2,4-oxadiazol-5-il)propan-2-il]morfinan-7-carboxamida

$C_{32}H_{34}N_4O_6$



naloxegolum

naloxegol — 4,5α-epoxy-6α-[(3,6,9,12,15,18,21-heptaoxadocosan-1-yl)oxy]-17-(prop-2-en-1-yl)morphinan-3,14-diol

naloxégol — 4,5α-époxy-6α-[(3,6,9,12,15,18,21-heptaoxadocosan-1-yl)oxy]-17-(prop-2-én-1-yl)morphinane-3,14-diol

naloxegol — 4,5α-epoxi-6α-[(3,6,9,12,15,18,21-heptaoxadocosan-1-il)oxi]-17-(prop-2-en-1-il)morfinan-3,14-diol

$C_{34}H_{53}NO_{11}$



narnatumabum #

narnatumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* MST1R (macrophage stimulating 1 receptor, macrophage stimulating protein receptor, MSP receptor, c-met-related tyrosine kinase, protein-tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV3-7*01 (95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) - IGHG1*03 (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) - IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (231-231":234-234")-bisdisulfide dimer

narnatumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* MST1R (récepteur 1 stimulant le macrophage, récepteur de la protéine stimulant le macrophage, récepteur de la MSP, tyrosine kinase apparentée à c-met, protéine-tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV3-7*01 (95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) - IGHG1*03 (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) - IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

narnatumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* MST1R (receptor 1 estimulante el macrófago, receptor de la proteína estimulante el macrófago, receptor de la MSP, tirosina kinasa relacionada con c-met, proteína-tirosina kinase 8, PTK8, RON, p185-Ron, CD136)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-7*01 (95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) - IGHG1*03 (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) - IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYLMTWVRQA PGKGLEWVAN  50
IKQDGSEKYY VDSVKGRFTI SRDNAKNSLN LQMNSLRAED TAVYYCTRDG 100
YSSGRHYGMD VWGQGTTVIV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-2105 266-326 372-430
22''-96'' 149''-205'' 266''-326'' 372''-430''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 225-214' 225''-214'''
Inter-H-H 231-231'' 234-234''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

302, 302''

navarixinum

navarixin — 2-hydroxy-*N,N*-dimethyl-3-[(2-{[(1*R*)-1-(5-methylfuran-2-yl)propyl]amino}-3,4-dioxocyclobut-1-en-1-yl)amino]benzamide

navarixine — 2-hydroxy-*N,N*-diméthyl-3-[(2-{[(1*R*)-1-(5-méthylfuran-2-yl)propyl]amino}-3,4-dioxocyclobut-1-én-1-yl)amino]benzamide

navarixina — 2-hidroxi-*N,N*-dimetil-3-[(2-{[(1*R*)-1-(5-metilfuran-2-il)propil]amino}-3,4-dioxociclobut-1-en-1-il)amino]benzamida

$C_{21}H_{23}N_3O_5$



nelociguatum

nelociguat — methyl (4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl)carbamate

nélociguat — (4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl)carbamate de méthyle

nelociguat — (4,6-diamino-2-{1-[(2-fluorofenil)metil]-1*H*-pirazolo[3,4-*b*]piridin-3-il}pirimidin-5-il)carbamato de metilo

$C_{19}H_{17}FN_8O_2$



nintedanibum

nintedanib — methyl (3*Z*)-3-[({4-[*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylate

nintédanib — (3*Z*)-3-[({4-[*N*-méthyl-2-(4-méthylpipérazin-1-yl)acétamido]phényl}amino)(phényl)méthylidène]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylate de méthyle

nintedanib — (3*Z*)-3-[({4-[*N*-metil-2-(4-metilpiperazin-1-il)acetamido]fenil}amino)(fenil)metiliden]-2-oxo-2,3-dihidro-1*H*-indol-6-carboxilato de metilo

$C_{31}H_{33}N_5O_4$



nivocasanum

nivocasan — (5*R*)-*N*-[(2*S*,3*S*)-2-(fluoromethyl)-2-hydroxy-5-oxooxolan-3-yl]-3-(isoquinolin-1-yl)-5-(propan-2-yl)-4,5-dihydro-1,2-oxazole-5-carboxamide

nivocasan — (5*R*)-*N*-[(2*S*,3*S*)-2-(fluorométhyl)-2-hydroxy-5-oxooxolan-3-yl]-3-(isoquinoléin-1-yl)-5-(propan-2-yl)-4,5-dihydro-1,2-oxazole-5-carboxamide

nivocasán — (5*R*)-*N*-[(2*S*,3*S*)-2-(fluorometil)-2-hidroxi-5-oxooxolan-3-il]-3-(isoquinolin-1-il)-5-(propan-2-il)-4,5-dihidro-1,2-oxazol-5-carboxamida

$C_{21}H_{22}FN_3O_5$



oclacitinibum

oclacitinib — *N*-methyl{*trans*-4-[methyl(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide

oclacitinib — *N*-méthyl[*trans*-4-(méthyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-ylamino)cyclohexyl]méthanesulfonamide

oclacitinib — *N*-metil{*trans*-4-[metil(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]ciclohexil}metanosulfonamida

$C_{15}H_{23}N_5O_2S$



olcorolimusum

olcorolimus — (3*S*,6*S*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihydroxy-3-{(1*R*)-1-[(1*S*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34[a]-icosahydro-11*H*-23,27-epoxypyrido[2,1-*c*][1,4]oxaazacyclohentriacontine-1,11,28,29(31*H*)-tetrone

olcorolimus — (3*S*,6*S*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihydroxy-3-{(1*R*)-1-[(1*S*,3*R*,4*R*)-4-hydroxy-3-méthoxycyclohexyl)propan-2-yl}-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34[a]-icosahydro-11*H*-23,27-époxypyrido[2,1-*c*][1,4]oxaazacyclohentriacontine-1,11,28,29(31*H*)-tétrone

olcorolimús — (3*S*,6*S*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihidroxi-3-{(1*R*)-1-[(1*S*,3*R*,4*R*)-4-hidroxi-3-metoxiciclohexil)propan-2-il}-10,21-dimetoxi-6,8,12,14,20,26-hexametil-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34[a]-icosahidro-11*H*-23,27-epoxipirido[2,1-*c*][1,4]oxaazaciclohentriacontina-1,11,28,29(31*H*)-tetrona

$C_{51}H_{81}NO_{12}$



ordopidinum

ordopidine 1-ethyl-4-[2-fluoro-3-(methanesulfonyl)phenyl]piperidine

ordopidine 1-éthyl-4-[2-fluoro-3-(méthylsulfonyl)phényl]pipéridine

ordopidina 1-etil-4-[2-fluoro-3-(metanosulfonil)fenil]piperidina

$C_{14}H_{20}FNO_2S$ 871351-60-9



ozoralizumabum #

ozoralizumab immunoglobulin single chain VH-VH'-VH, trivalent bispecific anti-[*Homo sapiens* TNF (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNFA, TNF-alpha)] VH and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HAS)] VH', humanized *Lama glama* monoclonal antibody;
scVH-VH'-VH (1-363) [humanized VH (*Homo sapiens* IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (105)) [8.8.8] (1-115) - 9-mer linker (tetraglycyl-seryl-triglycyl-seryl) (116-124) -humanized VH' (*Homo sapiens* IGHV3-23*04 (89.60%) -(IGHD)-IGHJ1*01 W118>S (229), G119>S (230) [8.8.8] (125-239) -9-mer linker (tetraglycyl-seryl-triglycyl-seryl) (240-248) -humanized VH (*Homo sapiens* IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (353)(249-363)

ozoralizumab immunoglobuline single chain VH-VH'-VH, trivalente bispécifique anti-[*Homo sapiens* TNF (facteur de nécrose tumorale, membre 2 de la superfamille du TNF, TNFSF2, TNFA, TNF-alpha)] VH et anti-[*Homo sapiens* ALB (albumine, sérum albumine humaine, SAH)] VH', anticorps monoclonal de *Lama glama* humanisé;
scVH-VH'-VH (1-363) [VH humanisé (*Homo sapiens* IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (105)) [8.8.8] (1-115) -9-mer linker (tétraglycyl-séryl-triglycyl-séryl) (116-124) -VH' humanisé (*Homo sapiens* IGHV3-23*04 (89.60%) -(IGHD)-IGHJ1*01 W118>S (229), G119>S (230) [8.8.8] (125-239) -9-mer linker (tétraglycyl-séryl-triglycyl-séryl) (240-248) -VH humanisé (*Homo sapiens* IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (353)(249-363)

ozoralizumab inmunoglobulina de cadena sencilla VH-VH'-VH, trivalente biespecífica anti-[TNF de *Homo sapiens* (factor de necrosis tumoral, miembro 2 de la superfamilia del TNF, TNFSF2, TNFA, TNF-alpha)] VH y anti-[*Homo sapiens* ALB (albumina, albumina sérica humana SAH)] VH', anticuerpo monoclonal de *Lama glama* humanizado;
scVH-VH'-VH (1-363) [VH humanizado (*Homo sapiens* IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (105)) [8.8.8] (1-115) - conector nonámero (tetraglicil-seril-triglicil-seril) (116-124) -VH' humanizado (*Homo sapiens* IGHV3-23*04 (89.60%) -(IGHD)-IGHJ1*01 W118>S (229), G119>S (230) [8.8.8] (125-239) - espaciador nonámero (tetraglicil-seril-triglicil-seril) (240-248) -VH humanizado (*Homo sapiens* IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (353)(249-363)

scVH-VH'-VH chain / Chaîne scVH-VH'-VH / Cadena scVH-VH'-VH

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYWMYWVRQA PGKGLEWVSE  50
INTNGLITKY PDSVKGRFTI SRDNAKNTLY LQMNSLRPED TAVYYCARSP 100
SGFNRGQGTL VTVSSGGGGS GGGSEVQLVE SGGGLVQPGN SLRLSCAASG 150
FTFSSFGMSW VRQAPGKGLE WVSSISGSGS DTLYADSVKG RFTISRDNAK 200
TTLYLQMNSL RPEDTAVYYC TIGGSLSRSS QGTLVTVSSG GGGSGGGSEV 250
QLVESGGGLV QPGGSLRLSC AASGFTFSDY WMYWVRQAPG KGLEWVSEIN 300
TNGLITKYPD SVKGRFTISR DNAKNTLYLQ MNSLRPEDTA VYYCARSPSG 350
FNRGQGTLVT VSS                                         363
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 22-96 146-220 270-34

pateclizumabum #

pateclizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* LTA (lymphotoxin alpha, TNFSF1, tumor necrosis factor superfamily member 1, LT)], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -*Homo sapiens* IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (227-227":230-230")-bisdisulfide dimer

patéclizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* LTA (lymphotoxine alpha, TNFSF1, membre 1 de la superfamille du facteur de nécrose tumorale, LT)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -*Homo sapiens* IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

pateclizumab

inmunoglobulina G1-kappa, anti-[LTA *de Homo sapiens* (linfotoxina alfa, TNFSF1, miembro 1 de la superfamilia del factor de necrosis tumoral, LT)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizada (*Homo sapiens* IGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -*Homo sapiens* IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYVIHWVRQA PGKGLEWVGY  50
NNPYNAGTNY NEKFKGRFTI SSDKSKNTAY LQMNSLRAED TAVYYCSRPT 100
MLPWFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQAVS SAVAWYQQKP GKAPKLLIYS  50
ASHRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQE SYSTPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 221-214' 221"-214'"
Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

298, 298"

pegadricasum #

pegadricase

pegylated Urate Oxidase from *Candida utilis*, [198-threonine(S>T)]uricase (EC 1.7.3.3, urate oxidase) *Pichia jadinii* (Yeast) (*Candida utilis*) tetramer, 6-amino group of an average of 3 lysine residues, mostly in position 16, 19, and 85 of each monomer, are amidified with α-(3-carboxypropanoyl)-ω-methoxypoly(oxyethylene)

pégadricase

urate oxidase de *Candida utilis* pégylée, [198-thréonine(S>T)]uricase (EC 1.7.3.3, urate oxydase) *Pichia jadinii* (levure) (*Candida utilis*), tétramère, la fonction amine en 6 de certaines lysines, en moyenne 3, principalement en positions 16, 19, et 85 de chaque monomère, sont amidifiées par le α-(3-carboxypropanoyl)-ω-méthoxypoly(oxyéthylène)

pegadricasa

urato oxidasa de *Candida utilis* pegilada, [198-treonina(S>T)]uricasa (EC 1.7.3.3, urato oxidasa) *Pichia jadinii* (levadura) (*Candida utilis*), tetrámero, la función amina en 6 de ciertas lisinas, 3 por término medio, principalmente en las posiciones 16, 19, y 85 de cada monómero, está amidificada con α-(3-carboxipropanoil)-ω-metoxipoli(oxietileno)

Monomer / Monomère / Monómero

```
MSTTLSSSTY GKDNVKFLKV KKDPQNPKKQ EVMEATVTCL LEGGFDTSYT  50
EADNSSIVPT DTVKNTILVL AKTTEIWPIE RFAAKLATHF VEKYSHVSGV 100
SVKIVQDRWV KYAVDGKPHD HSFIHEGGEK RITDLYYKRS GDYKLSSAIK 150
DLTVLKSTGS MFYGYNKCDF TTLQPTTDRI LSTDVDATWV WDNKKIGTVY 200
DIAKAADKGI FDNVYNQARE ITLTTFALEN SPSVQATMFN MATQILEKAC 250
SVYSVSYALP NKHYFLIDLK WKGLENDNEL FYPSPHPNGL IKCTVVRKEK 300
TKL                                                    303
```

Modified residues / Résidus modifiés / Residuos modificados

K
16, 19, 85
main pegylation sites
principaux sites pégylés
principios sitios pegilado



peginterferonum lambda-1a #

peginterferon lambda-1a

pegylated interferon lambda-1; pegylated interleukin 29; *N*-{3-[α-methylpoly(oxyethylene)oxy]propyl}-L-methionyl{[171-serine]human interleukin-29 (IFN-λ-1)-(7-181)-peptide}

péginterféron lambda-1a

interféron lambda-1 pégylé; interleukine-29 pégylée; *N*-{3-[α-méthylpoly(oxyéthylène)oxy]propyl}-L-méthionyl{[171-sérine] interleukine-29 humaine (IFN-λ-1)-(7-181)-peptide}

peginterferón lambda-1a

interferón lambda-1 pegilado; interleukina-29 pegilada; *N*-{3-[α-metilpoli(oxietileno)oxi]propil}-L-metionil{[171-serina] interleukina-29 humana (IFN-λ-1)-(7-181)-péptido}

$C_{875}H_{1408}N_{254}O_{251}S_5\ (C_2H_4O)_n$

```
     MKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS 50
SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH 100
TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV 150
TFNLFRLLTR DLKYVADGNL SLRTSTHPES T                    181
```

Modified residue / Résidu modifié / Residuo modificado



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
15-112 49-145

pegnivacoginum

pegnivacogin

a ribonucleic acid aptamer which binds Factor XIa; ester of 2'-*O*-methyl-5'-*O*-phosphonoguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3' →5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→3')-thimidine with 6-[(2,6-bis{*N*-[ω-methoxypoly(oxyethylene)carbonyl]}-DL-lysyl)amino]hexan-1-ol

pégnivacogin

acide ribonucleique aptamère se liant au Factor XIa;
ester de 2'-*O*-méthyl-5'-*O*-phosphonoguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→3')-thimidine avec 6-[(2,6-bis{*N*-[ω-méthoxypoly(oxyéthylène)carbonyl]}-DL-lysyl)amino]hexan-1-ol

pegnivacogina

aptámero de ácido ribomucléico que se une a Factor XIa;
éster of 2'-*O*-metil-5'-*O*-fosfonoguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→3')-timidina con 6-[(2,6-bis{*N*-[ω-metoxipoli(oxietileno)carbonil]}-DL-lisil)amino]hexan-1-ol

$C_{327}H_{422}F_{11}N_{114}O_{213}P_{31}\ (C_2H_4O)_n$

(3'-5')-R-pmG-mU-mG-mG-mA-dflC-dflU-mA-dflU-mA-dflC-dflC-mG-dflC-mG-dflU-mA-mA-dflU-mG-dflC-mU-G-mC-dflC-dflU-mC-mC-mA-mC3'-3'dT
Legend:
dfl = 2'-deoxy-2'-fluoro ; m = 2'-O-methyl ; p (as prefix) = 5'-phosphate

R- =



pimasertibum

pimasertib

N-[(2*S*)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamide

pimasertib

N-[(2*S*)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophényl)amino]pyridine-4-carboxamide

pimasertib

N-[(2*S*)-2,3-dihidroxipropil]-3-[(2-fluoro-4-iodofenil)amino]piridina-4-carboxamida

$C_{15}H_{15}FIN_3O_3$



recoflavonum

recoflavone {[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4*H*-chromen-7-yl]oxy}acetic acid

récoflavone acide {[2-(3,4-diméthoxyphényl)-5-méthoxy-4-oxo-4*H*-chromen-7-yl]oxy}acétique

recoflavona ácido {[2-(3,4-dimetoxifenil)-5-metoxi-4-oxo-4*H*-cromen-7-il]oxi}acético

$C_{20}H_{18}O_8$



rucaparibum

rucaparib 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6*H*-pyrrolo[4,3,2-*ef*][2]benzazepin-6-one

rucaparib 8-fluoro-2-{4-[(méthylamino)méthyl]phényl}-1,3,4,5-tétrahydro-6*H*-pyrrolo[4,3,2-*ef*][2]benzazépin-6-one

rucaparib 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6*H*-pirrolo[4,3,2-*ef*][2]benzazepin-6-ona

$C_{19}H_{18}FN_3O$



safotibantum

safotibant *N*-{[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl}-2-{2-[(4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy}-*N*-methylacetamide

safotibant *N*-{[4-(4,5-dihydro-1*H*-imidazol-2-yl)phényl]méthyl}-2-{2-[(4-méthoxy-2,6-diméthylbenzènesulfonyl)(méthyl)amino]éthoxy}-*N*-méthylacétamide

safotibant

N-{[4-(4,5-dihidro-1*H*-imidazol-2-il)fenil]metil}-2-{2-[(4-metoxi-2,6-dimetilbencenosulfonil)(metil)amino]etoxi}-*N*-metilacetamido

$C_{25}H_{34}N_4O_5S$



selepressinum

selepressin

vasopressin type 1a (V1a) receptor agonist; [2-L-phenylalanine,3-L-isoleucine,4-(6-oxo-L-lysine),8-[5-*N*-(propan-2-yl)-L-ornithine]]human vasopressin

sélépressine

agoniste du récepteur de la vasopressine type 1a (V1a); [2-L-phénylalanine,3-L-isoleucine,4-(6-oxo-L-lysine),8-[5-*N*-(propan-2-yl)-L-ornithine]]vasopressine humaine

selepresina

agonista del receptor de la vasopresina tipo 1ª (V1a); [2-L-fenillalanina,3-L-isoleucina,4-(6-oxo-L-lisina),8-[5-*N*-(propan-2-yl)-L-ornitina]]vasopresina humana

$C_{46}H_{73}N_{13}O_{11}S_2$



sepantronii bromidum

sepantronium bromide

1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-[(pyrazin-2-yl)methyl]-4,9-dihydro-1*H*-naphtho[2,3-*d*]imidazolium bromide

bromure de sépantronium

bromure de 1-(2-méthoxyéthyl)-2-méthyl-4,9-dioxo-3-[(pyrazin-2-yl)méthyl]-4,9-dihydro-1*H*-naphto[2,3-*d*]imidazolium

bromuro de sepantronio

bromuro de 2-metil-1-(2-metoxietil)-4,9-dioxo-3-[(pirazin-2-il)metil]-4,9-dihidro-1*H*-nafto[2,3-*d*]imidazolio

$C_{20}H_{19}BrN_4O_3$



serelaxinum

serelaxin — human relaxin 2 (relaxin H2)

sérélaxine — rélaxine 2 humaine (rélaxine H2)

serelaxina — relaxina 2 humana (relaxina H2)

$C_{256}H_{408}N_{74}O_{74}S_8$

B chain / Chaîne B / Cadena B
DSWMEEVIKL CGRELVRAQI AICGMSTWS 29

A chain / Chaîne A / Cadena A
QLYSALANKC CHVGCTKRSL ARFC 24'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
10'-15' 11-11' 23-24'

Modified residue / Résidu modifié / Residuo modificado

Q
1'
L-pyroglutamic acid



seridopidinum

seridopidine — 1-ethyl-4-[3-fluoro-5-(methanesulfonyl)phenyl]piperidine

séridopidine — 1-éthyl-4-[3-fluoro-5-(méthylsulfonyl)phényl]pipéridine

seridopidina — 1-etil-4-[3-fluoro-5-(metanosulfonil)fenil]piperidina

$C_{14}H_{20}FNO_2S$



simeprevirum

simeprevir — (2*R*,3a*R*,10*Z*,11a*S*,12a*R*,14a*R*)-*N*-(cyclopropanesulfonyl)-2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[*c*]cyclopropa[*g*][1,6]diazacyclotetradecine-12a(1*H*)-carboxamide

siméprévir — (2*R*,3a*R*,10*Z*,11a*S*,12a*R*,14a*R*)-*N*-(cyclopropanesulfonyl)-2-({7-méthoxy-8-méthyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinoléin-4-yl}oxy)-5-méthyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tétradécahydrocyclopenta[*c*]cyclopropa[*g*][1,6]diazacyclotétradécine-12a(1*H*)-carboxamide

simeprevir — (2*R*,3a*R*,10*Z*,11a*S*,12a*R*,14a*R*)-*N*-(ciclopropanosulfonil)-2-({7-metoxi-8-metil-2-[4-(propan-2-il)-1,3-tiazol-2-il]quinolin-4-il}oxi)-5-metil-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahidrociclopenta[*c*]ciclopropa[*g*][1,6]diazaciclotetradecina-12a(1*H*)-carboxamida

$C_{38}H_{47}N_5O_7S_2$



siponimodum

siponimod — 1-({4-[(1*E*)-1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid

siponimod — acide 1-({4-[(1*E*)-1-({[4-cyclohexyl-3-(trifluorométhyl)phényl]méthoxy}imino)éthyl]-2-éthylphényl}méthyl)azétidine-3-carboxylique

siponimod — ácido 1-({4-[(1*E*)-1-({[4-ciclohexil-3-(trifluorometil)fenil]metoxi}imino)etil]-2-etilfenil}metil)azetidina-3-carboxílico

$C_{29}H_{35}F_3N_2O_3$



sirukumabum #

sirukumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6 (interleukin 6, IL-6)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-7*01 (87.80%) -(IGHD)-IGHJ6*01) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (87.40%) -IGKJ4*01) [5.3.9] (1'-107') -IGKC*01 (107'-213')]; (228-231":228-231")-bisdisulfide dimer

sirukumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6 (interleukine 6, IL-6)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV3-7*01 (87.80%) -(IGHD)-IGHJ6*01) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (87.40%) -IGKJ4*01) [5.3.9] (1'-107') -IGKC*01 (107'-213')]; dimère (228-228":231-231")-bisdisulfure

sirukumab

inmunoglobulina G1-kappa, anti-[IL6 de *Homo sapiens* (interleukina 6, IL-6)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-7*01 (87.80%) -(IGHD)-IGHJ6*01) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (87.40%) -IGKJ4*01) [5.3.9] (1'-107') -IGKC*01 (107'-213')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS PFAMSWVRQA PGKGLEWVAK  50
ISPGGSWTYY SDTVTGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARQL 100
WGYYALDIWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCSASISVS YMYWYQQKPG QAPRLLIYDM  50
SNLASGIPAR FSGSGSGTDF TLTISSLEPE DFAVYYCMQW SGYPYTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    146-202   263-323   369-427
         22"-96"  146"-202" 263"-323" 369"-427"
Intra-L  23'-87'   133'-193'
         23'"-87'" 133'"-193'"
Inter-H-L  222-213'  222"-213'"
Inter-H-H  228-228"  231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

solithromycinum

solithromycin

(3a*R*,4*R*,7*S*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-1-{4-[4-(3-aminophenyl)-1*H*-1,2,3-triazol-1-yl]butyl}-4-ethyl-7-fluoro-11-methoxy-3^a,7,9,11,13,15-hexamethyl-10-{[trideoxy-(dimethylamino)-β-D-hexopyranosyl]oxy}octahydro-2*H*-oxacyclotetradecino[4,3-*b*][1,3]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tetraone

solithromycine

(3a*S*,4*R*,7*S*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-1-{4-[4-(3-aminophényl)-1*H*-1,2,3-triazol-1-yl]butyl}-4-éthyl-7-fluoro-11-méthoxy-3a,7,9,11,13,15-hexaméthyl-10-{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-*xylo*-hexopyranosyl]oxy}octahydro-2*H*-oxacyclotétradécino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tétrone

solitromicina

(3a*R*,4*R*,7*S*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-1-{4-[4-(3-aminofenil)-1*H*-1,2,3-triazol-1-il]butil}-4-etil-7-fluoro-3^a,7,9,11,13,15-hexametil-11-metoxi-10-{[tridesoxi-(dimetilamino)-β-D-hexopiranosil]oxi}octahidro-2*H*-oxaciclotetradecino[4,3-*b*][1,3]oxazol-2,6,8,14(1*H*,7*H*,9*H*)-tetraona

$C_{43}H_{65}FN_6O_{10}$ 760981-83-7



spriferminum #

sprifermin — L-methionyl[human fibroblast growth factor 18 (FGF-18, zFGF5)-(1-169)-peptide

sprifermine — L-méthionyl[facteur 18 de croissance du fibroblaste humain (FGF-18, zFGF5)-(1-169)-peptide]

esprifermina — L-metionil[factor 18 de crecimiento de fibroblastos humanos (FGF-18, zFGF5)-(1-169)-péptido]

$C_{876}H_{1396}N_{258}O_{256}S_6$

```
                                                                M
EENVDFRIHV  ENQTRARDDV  SRKQLRLYQL  YSRTSGKHIQ  VLGRRISARG  50
EDGDKYAQLL  VETDTFGSQV  RIKGKETEFY  LCMNRKGKLV  GKPDGTSKEC  100
VFIEKVLENN  YTALMSAKYS  GWYVGFTKKG  RPRKGPKTRE  NQQDVHFMKR  150
YPKGQPELQK  PFKYTTVTK                                      169
```

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
82-100

suvorexantum

suvorexant — [(7*R*)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl]methanone

suvorexant — [(7*R*)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-méthyl-1,4-diazépan-1-yl][5-méthyl-2-(2*H*-1,2,3-triazol-2-yl)phényl]méthanone

suvorexant — [(7*R*)-4-(5-cloro-1,3-benzoxazol-2-il)-7-metil-1,4-diazepan-1-il][5-metil-2-(2*H*-1,2,3-triazol-2-il)fenil]metanona

$C_{23}H_{23}ClN_6O_2$



tabalumabum #

tabalumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* TNFSF13B (tumor necrosis factor superfamily member 13B, BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, B cell activating factor, B lymphocyte stimulator, CD257)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-450) [*Homo sapiens* VH (IGHV4-34*01 (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01 hinge S10>P (231) (124-450)], (137-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; (229-229":232-232")-bisdisulfide dimer

tabalumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* TNFSF13B (membre 13B de la superfamille du facteur de nécrose tumorale, BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, facteur d'activation des cellules B, stimulateur des lymphocytes B, CD257)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-450) [*Homo sapiens* VH (IGHV4-34*01 (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01 charnière S10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

tabalumab — inmunoglobulina G4-kappa, anti-[TNFSF13B *de Homo sapiens* (miembro 13B de la superfamilia del factor de necrosis tumoral, BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, factor de activación de células B, estimulante de linfocitos B, CD257)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma4 (1-450) [VH de *Homo sapiens* (IGHV4-34*01 (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01 bisagra S10>P (231) (124-450)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE  50
INHSGSTNYN PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARGYY 100
DILTGYYYYF DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350
VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD STLTISSLEP EDFAVYYCQQ RSNWPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSNTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-95    150-206    264-324    370-428
         22"-95"  150"-206"  264"-324"  370"-428"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L  137-214'  137"-214'"
Inter-H-H  229-229"  232-232"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

300, 300"

tefinostatum

tefinostat — cyclopentyl (2*S*)-2-[({4-[8-(hydroxyamino)-8-oxooctanamido]phenyl}methyl)amino]-2-phenylacetate

téfinostat — (2*S*)-2-[({4-[8-(hydroxyamino)-8-oxooctanamido]phényl}methyl)amino]-2-phénylacétate de cyclopentyle

tefinostat — (2*S*)-2-[({4-[8-(hidroxiamino)-8-oxooctanamido]fenil}metil)amino]-2-fenilacetato de ciclopentilo

$C_{28}H_{37}N_3O_5$



tofacitinibum

tofacitinib — 3-{(3*R*,4*R*)-4-methyl-3-[methyl(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile

tofacitinib — 3-{(3*R*,4*R*)-4-méthyl-3-[méthyl(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]pipéridin-1-yl}-3-oxopropanenitrile

tofacitinib — 3-{(3*R*,4*R*)-4-metil-3-[metil(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]piperidin-1-il}-3-oxopropanonitrilo

$C_{16}H_{20}N_6O$



trametinibum

trametinib — *N*-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-*d*]pyrimidin-1(2*H*)-yl}phenyl)acetamide

tramétinib — *N*-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophényl)amino]-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydropyrido[4,3-*d*]pyrimidin-1(2*H*)-yl}phényl)acétamide

trametinib — *N*-(3-{3-ciclopropil-5-[(2-fluoro-4-iodofenil)amino]-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidropirido[4,3-*d*]pirimidin-1(2*H*)-il}fenil)acetamida

$C_{26}H_{23}FIN_5O_4$



upamostatum

upamostat — ethyl 4-{(2*S*)-3-{3-[(*E*)- *N*'-hydroxycarbamimidoyl]phenyl}-2-[2,3,5-tri(propan-2-yl)benzenesulfonamido]propanoyl}piperazine-1-carboxylate

upamostat — 4-{(2*S*)-3-{3-[(*E*)- *N*'-hydroxycarbamimidoyl]phényl}-2-[2,3,5-tri(propan-2-yl)benzènesulfonamido]propanoyl}pipérazine-1-carboxylate d'éthyle

upamostat — 4-{(2*S*)-3-{3-[(*E*)- *N*'-hidroxicarbamimidoil]fenil}-2-[2,3,5-tri(propan-2-il)bencenosulfonamido]propanoil}piperazina-1-carboxilato de etilo

$C_{32}H_{47}N_5O_6S$



vatelizumabum #

vatelizumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* ITGA2 (integrin alpha 2, CD49b, GPIa, subunit of the alpha2beta1 integrin (VLA-2, collagen receptor))], humanized monoclonal antibody; gamma4 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV4-59*01 (79.40%) -(IGHD)-IGHJ6*01) [8.7.13] (1-119) -*Homo sapiens* IGHG4*01 (120-446)], (133-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV6D-41*01 (77.90%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (225-225":228-228")-bisdisulfide dimer

vatélizumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* ITGA2 (intégrine alpha 2, CD49b, GPIa, sous-unité de l'intégrine alpha2bêta1 (VLA-2, récepteur du collagène))], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-446) [VH humanisé (*Homo sapiens* IGHV4-59*01 (79.40%) -(IGHD)-IGHJ6*01) [8.7.13] (1-119) -*Homo sapiens* IGHG4*01 (120-446)], (133-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV6D-41*01 (77.90%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (225-225":228-228")-bisdisulfure

vatelizumab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* ITGA2 (integrina alfa 2, CD49b, GPIa, subunidad de la integrina alfa2beta1 (VLA-2, receptor del colageno))], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-446) [VH humanizada (*Homo sapiens* IGHV4-59*01 (79.40%) -(IGHD)-IGHJ6*01) [8.7.13] (1-119) -*Homo sapiens* IGHG4*01 (120-446)], (133-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizada (*Homo sapiens* IGKV6D-41*01 (77.90%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGFSLT NYGIHWIRQP PGKGLEWLGV  50
IWARGFTNYN SALMSRLTIS KDNSKNQVSL KLSSVTAADT AVYYCARAND 100
GVYYAMDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPSCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DFVMTQSPAF LSVTPGEKVT ITCSAQSSVN YIHWYQQKPD QAPKKLIYDT  50
SKLASGVPSR FSGSGSGTDY TFTISSLEAE DAATYYCQQW TTNPLTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	146-202	260-320	366-424
	22"-95"	146"-202"	260"-320"	366"-424"
Intra-L	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L	133-213'	133"-213'"		
Inter-H-H	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

296, 296"

* *"INN for pharmaceutical substances: Names for radicals, groups & others"* document available at / document disponible à / documento disponible en :
http://www.who.int/medicines/services/inn/publication/en/index.html

Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 6
(Chronicle of the WHO, December 1959, Vol. 13, No. 12)

p. 468 **mecamylaminum**
mecamylamine *replace the chemical name by the following*

(1*RS*,2*SR*,4*SR*)-*N*,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine

Denominations communes internationales recommandées (DCI Rec.): Liste 6
(Chronique de l'OMS, Vol. 13, No. 12, décembre 1959)

p. 488 **mecamylaminum**
mécamylamine *remplacer le nom chimique par le suivant*

(1*RS*,2*SR*,4*SR*)-*N*,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 6
(Crónica de la OMS, Vol. 13, No. 12, diciembre de 1959)

p. 501 **mecamylaminum**
mecamilamina *sustitúyase el nombre químico por el siguiente*

(1*RS*,2*SR*,4*SR*)-*N*,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina

Recommended International Non Proprietary Names (Rec. INN): List 31
(WHO Drug Information, Vol. 5, No. 3, 1991)

p. 17 **beraprostum**
beraprost *replace the chemical name and the structure by the following ones*

rac-4-{(1*R*,2*R*,3a*S*,8b*S*)-2-hydroxy-1-[(1*E*,3*S*,4*RS*)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl}butanoic acid



its epimer at C* and their enantiomers
son épimère en C* et leurs énantiomères
su epímero al C* y sus enantiómeros

Denominations communes internationales recommandées (DCI Rec.): Liste 31
(Informations pharmaceutiques OMS, Vol. 5, No. 3, 1991)

p. 18 **beraprostum**
béraprost

remplacer le nom chimique et la structure par les suivants

acide *rac*-4-{(1*R*,2*R*,3a*S*,8b*S*)-2-hydroxy-1-[(1*E*,3*S*,4*RS*)-3-hydroxy-4-méthyloct-1-én-6-ynyl]-2,3,3a,8b-tétrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl}butanoïque



its epimer at C* and their enantiomers
son épimère en C* et leurs énantiomères
su epímero al C* y sus enantiómeros

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 31
(Información farmacéutica OMS, Vol. 5, No. 3, 1991)

p. 18 **beraprostum**
beraprost

sustitúyase el nombre químico y la estructura por los siguientes

ácido *rac*-4-{(1*R*,2*R*,3a*S*,8b*S*)-2-hidroxi-1-[(1*E*,3*S*,4*RS*)-3-hidroxi-4-metiloct-1-en-6-inil]-2,3,3a,8b-tetrahidro-1*H*-ciclopenta[*b*][1]benzofuran-5-il}butanoico



its epimer at C* and their enantiomers
son épimère en C* et leurs énantiomères
su epímero al C* y sus enantiómeros

Recommended International Non Proprietary Names (Rec. INN): List 62
Denominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 250	*delete/supprimer/suprimáse*	*insert/insérer/insertese*
	ingenoli mebutatum	**ingenoli mebutas**

Recommended International Non Proprietary Names (Rec. INN): List 63
Denominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 69 **olodaterolum**

olodaterol *replace the chemical name by the following*
olodatérol *remplacer le nom chimique par le suivant*
olodaterol *sustitúyase el nombre químico por el siguiente*

6-hydroxy-8-[(1*R*)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl]-2*H*-1,4-benzoxazin-3(4*H*)-one

6-hydroxy-8-[(1*R*)-1-hydroxy-2-{[1-(4-méthoxyphényl)-2-méthylpropan-2-yl]amino}éthyl]-2*H*-1,4-benzoxazin-3(4*H*)-one

6-hidroxi-8-[(1*R*)-1-hidroxi-2-{[1-(4-metoxifenil)-2-metilpropan-2-il]amino}etil]-2*H*-1,4-benzoxazin-3(4*H*)-ona

Recommended International Non Proprietary Names (Rec. INN): List 64
Denominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 24, No. 3, 2010)

p. 264 **condoliasum #**

condoliase *replace the structure by the following*
condoliase *remplacer la structure par la suivante*
condoliasa *sustitúyase la estructura por la siguiente*

```
ATSNPAFDPK NLMQSEIYHF AQNNPLADFS SDKNSILTLS DKRSIMGNQS 50
LLWKWKGGSS FTLHKKLIVP TDKEASKAWG RSSTPVFSFW LYNEKPIDGY 100
LTIDFGEKLI STSEAQAGFK VKLDFTGWRA VGVSLNNDLE NREMTLNATN 150
TSSDGTQDSI GRSLGAKVDS IRFKAPSNVS QGEIYIDRIM FSVDDARYQW 200
SDYQVKTRLS EPEIQFHNVK PQLPVTPENL AAIDLIRQRL INEFVGGEKE 250
TNLALEENIS KLKSDFDALN IHTLANGGTQ GRHLITDKQI IIYQPENLNS 300
QDKQLFDNYV ILGNYTTLMF NISRAYVLEK DPTQKAQLKQ MYLLMTKHLL 350
DQGFVKGSAL VTTHHWGYSS RWWYISTLLM SDALKEANLQ TQVYDSLLWY 400
SREFKSSFDM KVSADSSDLD YFNTLSRQHL ALLLLEPDDQ KRINLVNTFS 450
HYITGALTQV PPGGKDGLRP DGTAWRHEGN YPGYSFPAFK NASQLIYLLR 500
DTPFSVGESG WNNLKKAMVS AWIYSNPEVG LPLAGRHPFN SPSLKSVAQG 550
YYWLAMSAKS SPDKTLASIY LAISDKTQNE STAIFGETIT PASLPQGFYA 600
FNGGAFGIHR WQDKMVTLKA YNTNVWSSEI YNKDNRYGRY QSHGVAQIVS 650
NGSQLSQGYQ QEGWDWNRMQ GATTIHLPLK DLDSPKPHTL MQRGERGFSG 700
TSSLEGQYGM MAFDLIYPAN LERFDPNFTA KKSVLAADNH LIFIGSNINS 750
SDKNKNVETT LFQHAITPTL NTLWINGQKI ENMPYQTTLQ QGDWLIDSNG 800
NGYLITQAEK VNVSRQHQVS AENKNRQPTE GNFSSAWIDH STRPKDASYE 850
YMVFLDATPE KMGEMAQKFR ENNGLYQVLR KDKDVHIILD KLSNVTGYAF 900
YQPASIEDKW IKKVNKPAIV MTHRQKDTLI VSAVTPDLNM TRQKAATPVT 950
INVTINGKWQ SADKNSEVKY QVSGDNTELT FTSYFGIPQE IKLSPLP    997
```

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.